Engrail Therapeutics has completed a series A round led by Nan Fung Life Sciences as it targets a validated mechanism-based approach to nervous system treatments.
Nan Fung Life Sciences, the healthcare investment arm of property development conglomerate Nan Fung, led a $32m series A round for Engrail Therapeutics, a US-based developer of treatments for nervous system disorders.
Founded in 2019, Engrail is working on medicines that are focusing on the nervous system, using a biological understanding of disease to create drugs based on validated mechanisms and the most promising compounds.
The funding will support clinical development of the startup’s first product candidate, ENX-101. It has…
